Editorial: Pathophysiology and pharmacological treatments associated with liver failures

Chandana B Herath; Omar El Hiba; Xiang Zhou; Xuefeng Luo; Kaihui Lu

doi:10.3389/fphar.2024.1407835

Editorial: Pathophysiology and pharmacological treatments associated with liver failures

Front Pharmacol. 2024 Apr 12:15:1407835. doi: 10.3389/fphar.2024.1407835. eCollection 2024.

Authors

Chandana B Herath¹, Omar El Hiba², Xiang Zhou³, Xuefeng Luo⁴, Kaihui Lu⁵

Affiliations

¹ Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Australia.
² Laboratory of Anthropogenic, Biotechnology and Health, Nutritional Physiopathologies, Neurosciences and Toxicology Team, Faculty of Sciences, Chouaib Doukkali University, El Jadida, Morocco.
³ Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
⁴ Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.
⁵ Division of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany.

No abstract available

Keywords: Hepatology; hepatic encephalopathy; hepatic fibrosis; liver cancer; liver failures; pathophysiology; pharmacology.

Publication types

Editorial

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. CBH was supported by grant funding from the National Health and Medical Research Council (NHMRC) of Australia (APP1124125).